邹彤,杨杰孚

• 1:北京医院心内科

摘要(Abstract)：

<正>慢性心力衰竭(chronic heart failure,CHF)是一种复杂的临床症候群,是各类心脏病的严重阶段或终末期表现,发生率高,预后差,5年死亡率高达50%,与恶性肿瘤相似[1]。目前认为神经内分泌系统的激活是引起心肌细胞凋亡、心肌重塑的重要因素,因此,治疗CHF是阻断过分激活的神经内分泌系统。现已证实,血管紧张素转化酶抑制药(angiotensin

关键词(KeyWords)： 慢性心力衰竭;多点起搏;迷走神经

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 邹彤,杨杰孚

参考文献(References)：

• [1]Mc Murray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC.Eur J Heart Fail,2012,14(8):803-869.
• [2]Abraham WT,Fisher WG,Smith AL,et al.Cardiac resynchronization in chronic heart failure.N Engl J Med,2002,346(24):1845-1853.
• [3]Cleland JG,Daubert JC,Erdmann E,et al.The effect of cardiac resynchronization on morbidity and mortality in heart failure.N Eng J Med,2005,352(15):1539-1549.
• [4]Moss AJ,Hall WJ,Cannom DS,et al.Cardiac-resynchronization therapy for the prevention of heart-failure events.N Engl J Mad,2009,361(14):1329-1338.
• [5]Brignole M,Auricchio A,Baron-Esquivias G,et al.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology(ESC).Developed in collaboration with the European Heart Rhythm Association(EHRA).Eur Heart J,2013,34(29):2281-2329.
• [6]Tracy CM,Epstein AE,Darbar D,et al.2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.Circulation,2012,126(14):1784-1800.
• [7]张澍,黄德嘉,华伟,等.心脏再同步治疗慢性心力衰竭的建议(2013年修订版).中华心律失常学杂志,2013,17(4):247-261.
• [8]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014.中华心血管病杂志,2014,42(2):98-122.
• [9]Tomassoni G,Baker J,Corbisiero R,et al.Postoperative performance of the Quartet?left ventricular heart lead.J Cardiovasc Electrophysiol,2013,24(4):449-456.
• [10]Osca J,Alonso P,Cano,et al.The use of quadripolar left ventricular leads improves the hemodynamic response to cardiac resynchronization therapy.Pacing Clin Electrophysiol,2015,38(3):326-333.
• [11]Thibault B,Dubuc M,Khaity P,et al.Acute haemodynamie comparison of multisite and biventrieular pacing with a quadripolar left ventricular lead.Europace,2013,15(7):984-991.
• [12]Pappone C,'Calovi'c,Vicedomini G,et al.Multipoint left ventricular pacing improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients.Heart Rhythm,2014,11(3):394-401.
• [13]Gottlieb C,Klugerz B.Multipoint pacing:can we connect the dots to improve resynchronization therapy?Heart Rhythm,2014,11(3):402-403.
• [14]Zanon F,Baracca E,Pastore G,et al.Multipoint pacing by a left ventricular quadripolar lead improves the acute hemodynamic response to CRT compared with conventional biventricular pacing at any site.Heart Rhythm,2015,12(5):975-981.
• [15]Schwartz PJ,De Ferrari GM,Sanzo A,et al.Long-term vagal stimulation in patients with advanced heart failure.First experience in man.Eur J Hear Fail,2008,10(9):884-891.
• [16]Schwartz PJ,De Ferrari GM.Sympathetic-parasympathetic interaction in health and disease:abnormalities and relevance in heart failure.Heart Fail Rev,2011,16(2):101-107.
• [17]Premchand RK,Sharma K,Mittal S,et al.Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure:results of the ANTHEM-HF trial.J Card Fail,2014,20(11):808-816.
• [18]Gold MR,Van Veldhuisen DJ,Hauptman PJ,et al.Vagus Nerve Stimulation for the Treatment of Heart Failure:The INOVATEHF Trial.J Am Coll Cardiol,2016,68(2):149-158.
• [19]Tse HF,Turner S,Sanders P,et al.Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment(SCS HEART study):first-in-man experience.Heart Rhythm,2015,12(3):588-595.
• [20]Zipes DP,Neuzil P,Theres H,et al.Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure:The DEFEAT-HF Study.JACC Heart Fail,2016,4(2):129-136.
• [21]Abraham WT,Zile MR,Weaver FA,et al.Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction.JACC Heart Fail,2015,3(6):487-496.
• [22]Gronda E,Seravalle G,Brambilla G,et al.Chronicbaroreflex activation effects on sympathetic nerve traffic,baroreflex function,and cardiac haemodynamics in heart failure:a proof-ofconcept study.Eur J Heart Fail,2014,16(9):977-983.
• [23]Gronda E,Seravalle G,Trevano FQ,et al.Long-term chronic baroreflex activation:persistent efficacy in patients with heart failure and reduced ejection fraction.J Hypertens,2015,33(8):1704-1708.
• [24]Kadish A,Nademanne K,Volosin K,et al.A randomizedcontrolled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure.Am Heart J,2011,161(2):329-337.
• [25]Kuschyk J,Roeger S,Schneider R,et al.Efficacy and survival in patients with cardiac contractility modulation:Long-term single center experience in 81 patients.Int J Cardiol,2015,183:76-81.
• [26]Kloppe A,Lawo T,Mijic D,et al.Long-term survival with Cardiac Contractility Modulation in patients with NYHAⅡorⅢsymptoms and normal QRS duration.Int J Cardiol,2016,209:291-295.
• [27]Borggrefe MM,Lawo T,Butter C,et al.Randomized,double blind study of non-excitatory,cardiac contractility modulation electrical impulses for symptomatic heart failure.Eur Heart J,2008,29(8):1019-1028.